As the management scheduled a 1-to-33 reverse split in September the JE reached $9.60 before the market closed at 04:00 pm EDT. • {{ article.symbol }} • We hope that this article gives you a new perspective into what the truth is, so you can make a truly informed decision instead of being conned by short sellers and Adam Feuerstein. Already have an account? Recs: 2 Views: 0 : return to … CytoDyn (CytoDyn: CYDY) stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers. As previously reported in the 2015 Proxy, prior to the Company’s reincorporation into Delaware, the reverse stock split was similarly approved by the Company, as the sole stockholder of CytoDyn, and by the prior board of directors of CytoDyn, with the same possible ratios as described in Proposal 3. Right now there are so many OTC stocks that obsess most investors by price and uptrends. What is the upside if Nasdaq discounts the share price? The … And just this week, By late March, they’ll trade as HMBL. CYDY CytoDyn Inc: I see a reverse split in their future.....6-10 for 1....too many shares O/S. CYDY CytoDyn Inc (QB) Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) ... Reasons for the Reverse Stock Split (See pages 5 – 11): The Board believes that it is in the best interests of the Company and its stockholders to approve a reverse stock split of the Company’s outstanding Common Stock in order to grant the Board the discretionary authority to effect a reverse … The Reverse Stock Split will be effected at a whole number ratio between one-for-two and one-for-fifteen, to be determined by the Board of Directors prior to the Record Date. The reverse stock split will become effective October 29, 2019 (the “Effective Date”). Additionally, the Company announced a 1:750 reverse split of its outstanding common stock. Proposal 4. Network for Teaching Entrepreneurship (NFTE) NFTE Receives $600,000 Grant from American Student Assistance to Fund Expansion. The acquisition was accounted for as a reverse merger and recapitalization of the Company. CytoDyn expects to decide on the size of the reduction at the meeting, according to the filing. e-mail to a friend : printer-friendly add to library | More. Featured Maybe the management will apply for a 1-to-1000 reverse split by lifting up the price to over $10. REVERSE SPLIT. InvestorsHub.com, Inc. The new CUSIP number following the … The meeting is scheduled for Nov. 1 in Roseland, N.J., and is open to stockholders of record as of Sept. 22. Pursuant to the acquisition agreement, we were … That reason was squelched when the stock started the run from 26 cents to 1.5$ a year ago. Undertaking a reverse stock split reduces the shares of the company’s common stock in order to boost stock values per share. On November 1, 2017 the company got approval to execute a reverse stock split at the board’s discretion before August 28, 2018. Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million Closes 2020 with $20 million. Leronlimab and placebo are administered via subcutaneous injection. The company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on October 29, 2019 under the trading symbol “LDSRD”. Rising 18.18% has … Re: flyntrade #65874. By late March, they’ll trade as HMBL. © According to a Monday filing with the U.S. Securities and Exchange Commission, the drugmaker believes the reverse stock split will help it get listed on a national securities exchange, which it hopes to do in the next six months. Before next week’s trade OZSC will likely lure or attract as many investors as the strong demand will lead to stable growth. $10 initally after the split is of course, … There is no reason for a reverse split in CYDY shares. Can anyone tell me what benefit shareholders or Cytodyn would get from a reverse split. The Reverse Stock Split is expected to be effective on or about April 19, 2018, subject to postponement or withdrawal at the discretion of the Board. {{ article.headline | getDecodedUnicode }} The Board is asking shareholders to approve: a reverse split of the Company’s Common Stock and grant to the Board the authority to set the ratio for the reverse split at either one-for-three, one-for-four, one-for-five, one-for-six, one-for-seven or one-for-eight (the “Reverse Stock Split”), or not to complete the Reverse Stock Split, as determined in the discretion of the Board at any time before August 20, 2015; … Reasons for the Reverse Stock Split (See pages 26-28) : ... APPROVAL OF AN INCREASE IN THE NUMBER OF SHARES AUTHORIZED FOR ISSUANCE UNDER THE CYTODYN INC. 2012 EQUITY INCENTIVE PLAN GENERAL The Board has approved an amendment to the CytoDyn Inc. 2012 Equity Incentive Plan (as previously amended effective February 27, 2015, the “2012 Equity Incentive Plan”) … Name: Email Address: CytoDyn’s Phase 2b/3 trial to evaluate the efficacy and safety of leronlimab for patients with severe-to-critical COVID-19 indications is a two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study. CytoDyn is a little biotech that has worked diligently but unsuccessfully to develop a single therapy, variously named Pro 140, leronlimab, and Vyrologix. Patients are randomized to receive weekly doses of 700 mg leronlimab, or placebo. The undersigned hereby appoints Anthony D. Caracciolo and Nader Z. Pourhassan as proxies and attorneys-in-fact, with full power of substitution, and hereby authorizes them, or either of them, to represent and to vote, as designated below, all the shares of the common stock of … Post Views: 4,626. Please visit our Facebook page to leave comments on local stories. 2021 - #6019795 Give the proximity to the expiration of this approval and the recent CEO guidance a reverse stock split doesn’t appear likely at all. In addition, Vyera will invest $4 million in CytoDyn in the form of registered CytoDyn common stock. Cytodyn should be on the podium, not Gilead and their remdesivir with all its shortcomings. Hopefully they are right and this will be a non-issue in the next few weeks, if not sooner. Message Board: Public Reply | Private Reply | Keep | Replies : Post New Msg: Edit Msg | Previous | Next: Post# of 72341 (Total Views: 480) Posted On: 11/18/2020 1:12:33 PM. Looks like the 5 reverse split did not hurt HGEN at all. Vancouver biotechnology company CytoDyn Inc. will consider a reverse stock split to raise individual share prices. Commenting is no longer available on Columbian.com. Statement of Changes in Beneficial Ownership (4), WSGF's, Vaycaychella, Heats Up In $32 Billion Caribbean Vacation Market; Adds Six-Room Hotel To Portfolio Interests, The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think, PAOG Signals Bullish On CBD Pharmaceutical News With Cannabis Sector Heating Up, Securities Registration Statement (simplified Form) (s-3/a), ALYI ReVolt EV Motorbike Can Capture Huge Share Of African Ride-Share Market; Pre-Orders Reach 2000 Units, Biotech Companies; Recent Milestones and Potential Upside, Small Company Offering and Sale of Securities Without Registration (d), Companies on the Frontline, Helping Us Through the Pandemic, Vaycaychella; the Rise of World Series of Golf, Inc. (OTCMKTS: WSGF). CytoDyn, 1111 Main St., Suite 660, has been at work on an HIV treatment called PRO 140. In the last conference call the CEO Nader Pourhassan, stated he was not at all in favor of a reverse stock split. July 2, 2020 admin … Looks like the 5 reverse split did not hurt HGEN a. Our Business -----In October 2003 we entered into an Acquisition Agreement with CytoDyn of New Mexico, Inc., pursuant to which we effected a two for one reverse split of our common stock, and amended our articles of incorporation to change our name from Rexray Corporation to CytoDyn, Inc. Pursuant to the acquisition agreement, we were assigned the patent license agreement dated July 1, … [ February 26, 2021 ] Guardion Health stock tumbles after reverse stock split announcement Trading Ideas Search for: Home Newsmakers CytoDyn (OTC: CYDY) Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology CytoDyn (OTC: CYDY) Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology . Cytodyn's PRs multiplicate faster than viruses, and try to infect people's thoughts with misleading titles and analyses. CytoDyn Inc (CYDY) Message Board. Exchanges, like the New York Stock Exchange for example, typically require stock prices to hit a minimum level before a company can list its stock on the exchange. NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Reverse Stock Split reported on October 21, 2019 will be postponed per a subsequent notification received from FINRA after-market that they have decided to continue their … Receive latest stories and local news in your email: Please take a second to review our community guidelines, Late gains reverse most of an early slide on stock market, Stocks end mixed, ending a 6-day winning streak for S&P 500, Big Tech leads stocks to broad gains; GameStop collapses. Monday is the shorts’ last stand. First of all, let's put aside any doubts. Related: Pacific Ethanol (PEIX) reaches July 2017's position. This proxy is solicited on behalf of the Board of Directors of CytoDyn Inc. 1) The market would perceive reverse split as a sign of weakness, leading to likely hit on share price. Posted By: calstang. 2) Leadership strongly convicted that we are on the verge of major game-changing announcements which will take care of the share price issues. CytoDyn, 1111 Main St., Suite 660, has been at work on an HIV treatment called PRO 140. Create your free account. Recently, TSNP stock underwent a reverse stock split that reduced outstanding shares. It’s still the same OTC company with the same management team, running the same trials with the same future prospects, just at a somewhat lower market cap. March 20, 2018 We are writing to notify you, pursuant to one or more Warrants held by you to purchase shares of common stock, $0.001 par value per share (the “Common Stock”), of CytoDyn Inc., a Delaware corporation (the “Company”), that the Company expects to effect a reverse stock split (the “Reverse S. 2018-03-14: EX-99.1 The reverse stock split was previously approved by stockholders at the Annual Meeting of Stockholders held on August 3, 2020. CYTODYN, INC. (Exact name of registrant as specified in its charter) ... Mexico, Inc., pursuant to which we effected a one for two reverse split of our common stock, and amended our articles of incorporation to change our name from Rexray Corporation to CytoDyn, Inc. The company said the timing of the reverse split will take place, at the board's discretion, before the one-year anniversary of its 2021 annual shareholder meeting scheduled for May 4. with New York-based Vyera Pharmaceuticals LLC which agreed to pay upfront, regulatory and sales-based milestone payments of up to $87.5 million and a royalty of 50 percent on net sales. 20 hours ago the company announced the closing of its recapitalization plan and reconstitution of the board of directors. CytoDyn recently signed a $87.5 million licensing deal for commercializing Leronlimab to treat HIV. However, the stock now trades at $8.38 after losing 1.22 points in the premarket. {{ article.date }} {{ article.time }}, Edgar (US Regulatory) - 3/8/2021 5:28:38 PM, Edgar (US Regulatory) - 3/3/2021 5:23:39 PM, Edgar (US Regulatory) - 3/2/2021 8:32:38 AM, InvestorsHub NewsWire - 2/22/2021 6:18:20 AM, InvestorsHub NewsWire - 2/12/2021 6:26:34 AM, Edgar (US Regulatory) - 2/5/2021 9:08:48 AM, Edgar (US Regulatory) - 1/29/2021 8:32:33 AM, InvestorsHub NewsWire - 1/22/2021 9:48:20 AM, Edgar (US Regulatory) - 1/15/2021 4:31:46 PM, Edgar (US Regulatory) - 1/8/2021 8:32:57 AM, InvestorsHub NewsWire - 1/7/2021 8:00:00 AM, InvestorsHub NewsWire - 1/6/2021 9:48:29 AM, Edgar (US Regulatory) - 12/30/2020 6:03:52 AM, InvestorsHub NewsWire - 12/29/2020 9:50:07 AM, InvestorsHub NewsWire - 12/22/2020 8:05:00 AM, Edgar (US Regulatory) - 12/18/2020 5:41:20 PM, Edgar (US Regulatory) - 12/16/2020 11:00:01 AM, Edgar (US Regulatory) - 12/16/2020 6:04:03 AM, InvestorsHub NewsWire - 12/10/2020 12:30:12 PM, InvestorsHub NewsWire - 11/30/2020 8:35:00 AM, Edgar (US Regulatory) - 11/16/2020 4:57:41 PM, InvestorsHub NewsWire - 11/11/2020 9:29:26 AM, CytoDyn to release CD12 trial data on March 8, CytoDyn to file for rolling review of leronlimab in COVID-19 in U.S., U.K. and Canada, Securities Registration Statement (simplified Form) (s-3), CytoDyn in discussions with regulators after CD12 data in COVID-19, Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation.